Kevin Kunzmann is the associate editorial director for HCPLive. Prior to joining parent company MJH Life Sciences in 2017, he worked as a health care and government reporter for The Pocono Record, and as a freelance writer for NJ Advance Media, The Express-Times, The Daily Journal, and more. He graduated from Rowan University with a degree in journalism in 2015. In his spare time, he enjoys reading, cooking, running his dog, and complaining about the Mets. Follow him on Twitter @NotADoctorKevin or email him at kkunzmann@mjhlifesciences.com.
Investigators observed that patients treated with secukinumab were more likely to achieve Psoriasis Area Severity Index (PASI) 75/90/100 responses and Investigator’s Global Assessment (IGA) improvement at 52 weeks than those administered usetkinumab, regardless of their psoriatic arthritis (PsA) status.
A comparison of pooled phase 3 data showed patients treated with the IL-17A inhibitor fared better than those on ustekinumab, without influence from their PsA status.
The indication makes the IL-6 inhibitor the first biologic approved for treating pulmonary function in patients with the rare disease.
Our annual series is touching on the stories in medicine that occurred during this unforgettable time.
The monoclonal antibody has built on its 18-month portfolio with sustained renal benefits for the at-need patient group.
A new study contributes to the growing discussion around rheumatic disease treatment disparities.
Just 2% of observed older men to experience an indicative fracture received a diagnosis and treatment for osteoporosis over a four-year period.
New survey findings show the antimalarial drug's promotion for potential SARS-CoV-2 benefit early into the pandemic led to needing patients losing access.
An interview with a study author on implementing artificial intelligence into rheumatic care.
Data suggest patients administered tofacitinib for their arthritis do not face worsened risk, severity of flu infection.
The first 3 months of the pandemic were marked by a significant rate of patients changing or discontinuing medication without clinician guidance.
New data show patients with arthritis and psoriasis are far more likely to quarantine and isolate than similar patients, differentiating by treatment type.
New data from ACR 2020 assure concerns that patients with arthritis who test positive for COVID-19 may be at worse risk of ICU admission or even death.
More than three-fourths of online respondents expressed concern about providing in-person patient safety after COVID-19. Another 35% want to use telemedicine in their practice now.
The sBLA indication is the fifth for the IL17A inhibitor, which showed reduction of inflammatory signs and symptoms in treated patients at 52 weeks.
New findings comparing 3 decades of newly approved indications show the proportion of new approvals being supported by just 1 pivotal trial has quadrupled.
The GSK-branded Advil will be available as a dual-action pain reliever later this year.
A look back at the developments and interviews that caught the most attention this year.
How therapies are advancing treat-to-target strategies, while the field faces a physician shortage issue.
How drug classes such as biologics have given dermatologists confidence in clearing patients' skin.
A new study from CCR West compared the JAK inhibitor therapy to competitors across a clinical trial program involving 5 pivotal phase 3 studies.
The indication for the add-on monoclonal antibody makes it the first approved therapy for children with the rare vasculitis conditions.
A cohort assessment of patients treated in a rural academic-based clinic finds just 10% of patients were vaccinated for the disease their RA therapies put them at more risk for.
A new study shows adherence to current ACR guidelines for therapy results in improved disease activity scores.
New findings show, despite women making up a greater rate of internal medicine residents, subspecialty fellowships are at a greater disparity now than in 1991.
The human monoclonal antibody was previously approved for the treatment of adults with plaque psoriasis in July 2017.
The JAK inhibitor from AbbVie has shown significant benefit for RA patients over 2 weeks of treatment.
The JAK inhibitor could receive consideration as a rheumatoid arthritis therapy in both Europe and the US in the following year.
The recommendation was based on the SENSCIS trial results, orginally shared at ATS 2019 this year.